By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Grunenthal GmbH 

Pascalstraße 6

Aachen    52076  Germany
Phone: 0241-569-1111 Fax: 0241-569-1112



Company News
Grunenthal Has Acquired US-Based Thar Pharma To Expand Its Development Portfolio Of Treatment Options For CRPS (Complex Regional Pain Syndrome), A Serious, Disabling Orphan Disease 11/17/2016 9:05:15 AM
Gabriel Baertschi Takes Office As New CEO Of Grunenthal As Of October 1, 2016 10/4/2016 10:44:20 AM
A Research Consortium Under The Direction Of Grunenthal Will Receive A Grant Of €1.5 Million From The European Fund For Regional Development And The Federal State Of North Rhein-Westphalia 9/27/2016 11:47:08 AM
Grunenthal Appoints Gabriel Baertschi As Chairman Of The Corporate Executive Board And Chief Executive Officer Effective October 1, 2016 6/7/2016 10:41:51 AM
AstraZeneca PLC (AZN) Unloads Gout Drug Rights to Grunenthal in $230 Million+ Deal 6/2/2016 6:02:12 AM
Grunenthal Announces Exclusive License Agreement For Commercialization Of Innovative Surgical Glue In The EU And Latin America 5/12/2016 6:38:54 AM
Grunenthal To Acquire Almirall de Mexico, S.A. de C.V. 3/16/2016 7:02:14 AM
Patheon (PTI.TO) Selected By Grunenthal To Develop Drugs Using INTAC® Abuse Deterrent Formulations Technology 2/22/2016 12:24:47 PM
Grunenthal GmbH's Innovative Medicines Unit (IMU) Opens Its First Innovation Hub To Further Strengthen The Company's Networked Research And Development Approach 1/6/2016 9:11:11 AM
Depomed (DEPO) Acquires U.S. Rights To Late-Stage, First-In-Class Pain Product From Grunenthal GmbH 11/18/2015 6:32:37 AM